CD301 is a lectin with clear evidence of binding specifically to these glycans, and its potential usefulness for disease classification or as immunotherapeutic agents, especially in the hypo-glycoengineered context of osteosarcoma, employing glyco-engineered treatments, strongly warrants further research [64]. Here, CLEC10A is linked to osteosarcoma.